African Americans more likely to exhibit negative perceptions of cancer-related clinical trials
the ONA take:
According to new findings that will be presented at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, researchers from Fox Chase Cancer Center and Temple University in Philadelphia, Pennsylvania, have found that African Americans are more likely to display negative perceptions of participating in cancer-related clinical trials.
For the study, researchers identified 41 African Americans with an average age of 60 years. Of those, 54% had no enrolled in a clinical trial within the past 9 months.
Researchers found that non-participants believed that a clinical trial would make them sicker, that important information would be withheld from them, and that no one discussed clinical trial participation with them.
Those who participated in clinical trials felt their doctor had provided enough information in order to make an informed decisions about clinical trial participation and that trials offered the best possible treatment for their disease.
The findings suggest that African American patients with cancer should received detailed information regarding clinical trial participation and their treatment options.
African Americans are more likely to display negative perceptions of participating in cancer-related clinical trials.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|